| 1 |
Zhao W, Li X, Ren Q, Wang Q, Liao C, Ding T, Li P, Liu J. Molecular mechanism of miRNA regulating PD-L1 expression. Gene Reports 2023;31:101763. [DOI: 10.1016/j.genrep.2023.101763] [Reference Citation Analysis]
|
| 2 |
AbdulHussein AH, Al-Taee MM, Radih ZA, Aljuboory DS, Mohammed ZQ, Hashesh TS, Riadi Y, Hadrawi SK, Najafi M. Mechanisms of cancer cell death induction by triptolide. Biofactors 2023. [PMID: 36876465 DOI: 10.1002/biof.1944] [Reference Citation Analysis]
|
| 3 |
Farasati Far B, Vakili K, Fathi M, Yaghoobpoor S, Bhia M, Naimi-Jamal MR. The role of microRNA-21 (miR-21) in pathogenesis, diagnosis, and prognosis of gastrointestinal cancers: A review. Life Sci 2023;316:121340. [PMID: 36586571 DOI: 10.1016/j.lfs.2022.121340] [Reference Citation Analysis]
|
| 4 |
Wang Q, Li G, Ma X, Liu L, Liu J, Yin Y, Li H, Chen Y, Zhang X, Zhang L, Sun L, Ai J, Xu S. LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis. Cell Death Dis 2023;14:76. [PMID: 36725842 DOI: 10.1038/s41419-023-05609-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Dai M, Liu M, Yang H, Küçük C, You H. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol 2022;11:101. [DOI: 10.1186/s40164-022-00356-0] [Reference Citation Analysis]
|
| 6 |
Beserra DR, Alberca RW, Branco ACCC, Oliveira LM, de Souza Andrade MM, Gozzi-silva SC, Teixeira FME, Yendo TM, da Silva Duarte AJ, Sato MN, Xu B. Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity. Journal of Immunology Research 2022;2022:1-9. [DOI: 10.1155/2022/9764002] [Reference Citation Analysis]
|
| 7 |
Zhou Z, Liu Q, Zhang G, Mohammed D, Amadou S, Tan G, Zhang X. HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. Cancers 2022;14:3694. [DOI: 10.3390/cancers14153694] [Reference Citation Analysis]
|
| 8 |
Vaxevanis CK, Friedrich M, Tretbar SU, Handke D, Wang Y, Blümke J, Dummer R, Massa C, Seliger B. Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma. Clin Transl Med 2022;12:e934. [PMID: 35802807 DOI: 10.1002/ctm2.934] [Reference Citation Analysis]
|
| 9 |
Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 10 |
Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol 2022;15:83. [PMID: 35765040 DOI: 10.1186/s13045-022-01305-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 11 |
Ashrafizadeh M, Zarrabi A, Karimi-Maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioeng Transl Med 2023;8:e10353. [PMID: 36684065 DOI: 10.1002/btm2.10353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 12 |
Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res 2022;41:105. [PMID: 35317831 DOI: 10.1186/s13046-022-02293-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 14 |
Ashrafizadeh M, Zarrabi A, Mostafavi E, Aref AR, Sethi G, Wang L, Tergaonkar V. Non-coding RNA-based regulation of inflammation. Semin Immunol 2022;59:101606. [PMID: 35691882 DOI: 10.1016/j.smim.2022.101606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 15 |
Anaya-Ruiz M, Perez-Santos M. Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharm Pat Anal 2021. [PMID: 34875853 DOI: 10.4155/ppa-2021-0016] [Reference Citation Analysis]
|
| 16 |
Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 18 |
Yu Z, Liu Y, Li Y, Zhang J, Peng J, Gong J, Xia Y, Wang L. miRNA-338-3p inhibits glioma cell proliferation and progression by targeting MYT1L. Brain Res Bull 2021;179:1-12. [PMID: 34848272 DOI: 10.1016/j.brainresbull.2021.11.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 19 |
Gu J, Liu Y, Qi T, Qian W, Hu D, Feng W. Long non-coding RNA DUXAP8 elevates RCN2 expression and facilitates cell malignant behaviors and angiogenesis in cervical cancer via sponging miR-1297. Diagn Pathol 2021;16:105. [PMID: 34774078 DOI: 10.1186/s13000-021-01145-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Najafi S, Tan SC, Raee P, Rahmati Y, Asemani Y, Lee EHC, Hushmandi K, Zarrabi A, Aref AR, Ashrafizadeh M, Kumar AP, Ertas YN, Ghani S, Aghamiri S. Gene regulation by antisense transcription: A focus on neurological and cancer diseases. Biomed Pharmacother 2021;145:112265. [PMID: 34749054 DOI: 10.1016/j.biopha.2021.112265] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 21 |
Mirzaei S, Saebfar H, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Entezari M, Hushmandi K, Samarghandian S, Aref AR, Ashrafizadeh M, Khan H. MicroRNAs regulating SOX2 in cancer progression and therapy response. Expert Rev Mol Med 2021;23:e13. [PMID: 34583803 DOI: 10.1017/erm.2021.15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 22 |
Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. Front Cell Neurosci 2021;15:716747. [PMID: 34381337 DOI: 10.3389/fncel.2021.716747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Mirzaei S, Gholami MH, Zabolian A, Saleki H, Farahani MV, Hamzehlou S, Far FB, Sharifzadeh SO, Samarghandian S, Khan H, Aref AR, Ashrafizadeh M, Zarrabi A, Sethi G. Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. Pharmacol Res 2021;171:105759. [PMID: 34245864 DOI: 10.1016/j.phrs.2021.105759] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 24 |
Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel) 2021;13:3034. [PMID: 34204509 DOI: 10.3390/cancers13123034] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 25 |
Chen L, Musa AE. Boosting immune system against cancer by resveratrol. Phytother Res 2021. [PMID: 34101276 DOI: 10.1002/ptr.7189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 26 |
Han X, Liu J, Liu Y, Mou L, Li C. LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p. Cancer Manag Res 2021;13:4393-401. [PMID: 34103994 DOI: 10.2147/CMAR.S305547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021;29:1958-69. [PMID: 33932597 DOI: 10.1016/j.ymthe.2021.04.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 28 |
Delfi M, Sartorius R, Ashrafizadeh M, Sharifi E, Zhang Y, De Berardinis P, Zarrabi A, Varma RS, Tay FR, Smith BR, Makvandi P. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy. Nano Today 2021;38:101119. [PMID: 34267794 DOI: 10.1016/j.nantod.2021.101119] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 29 |
You L, Wu W, Wang X, Fang L, Adam V, Nepovimova E, Wu Q, Kuca K. The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev 2021;41:1622-43. [PMID: 33305856 DOI: 10.1002/med.21771] [Cited by in Crossref: 70] [Cited by in F6Publishing: 77] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 30 |
Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 14.0] [Reference Citation Analysis]
|
